Insulin and C-Peptide Testing
Insulin and C-peptide blood tests are two of the most diagnostically precise tools available for evaluating pancreatic beta-cell function and distinguishing between the major forms of diabetes mellitus. This page covers how each marker is produced, what laboratory results indicate, the clinical scenarios in which these tests are ordered, and the thresholds that guide diagnostic and treatment decisions. Understanding these tests is central to the broader landscape of endocrinology diagnostic practice.
Definition and scope
Insulin is a 51-amino-acid peptide hormone secreted by pancreatic beta cells in response to rising blood glucose. C-peptide — short for "connecting peptide" — is a 31-amino-acid byproduct of proinsulin cleavage. When proinsulin is cleaved in the beta cell secretory granule, one molecule of insulin and one molecule of C-peptide are released into the portal circulation in equimolar amounts.
This equimolar release is the defining feature that makes C-peptide clinically valuable: it serves as a direct surrogate for endogenous insulin secretion because, unlike insulin, it is not extracted by the liver during first-pass metabolism and is not present in exogenous insulin formulations. The American Diabetes Association (ADA) recognizes C-peptide measurement as a key tool in diabetes classification, particularly when distinguishing Type 1 from Type 2 diabetes or identifying monogenic (MODY) forms of the disease.
Both markers fall under the regulatory oversight framework that governs clinical laboratory testing in the United States. Laboratories performing insulin and C-peptide assays must comply with the Clinical Laboratory Improvement Amendments (CLIA), administered by the Centers for Medicare & Medicaid Services (CMS). Reference ranges vary by assay platform, which is why inter-laboratory result comparisons require caution. The broader regulatory context for endocrinology covers how federal and state frameworks apply to hormone testing and reporting requirements.
How it works
Both insulin and C-peptide are measured from a blood sample, typically via immunoassay. The standard protocol involves one of two collection approaches:
- Fasting measurement — Blood is drawn after a minimum 8-hour fast. This captures basal secretory function and baseline insulin resistance markers.
- Stimulated measurement — Blood is drawn 6 minutes after intravenous administration of 1 mg glucagon (the glucagon stimulation test), or at timed intervals following a standardized mixed meal (the mixed meal tolerance test, MMTT). Stimulated C-peptide values reflect the maximum residual beta-cell capacity.
The glucagon stimulation test, detailed in protocols published by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), produces peak C-peptide values that correlate closely with MMTT peak values. A peak stimulated C-peptide above 0.2 nmol/L is the threshold most widely cited in literature to distinguish preserved beta-cell function from near-total beta-cell loss.
Insulin assays measure circulating insulin in mIU/L or pmol/L (conversion factor: 1 mIU/L ≈ 6.945 pmol/L). Because exogenous insulin is immunologically indistinguishable from endogenous insulin in older radioimmunoassays — though newer two-site immunometric assays show improved specificity — C-peptide is the preferred marker in patients already receiving insulin therapy.
Common scenarios
Insulin and C-peptide testing are ordered across a defined set of clinical presentations:
- Diabetes classification — Differentiating Type 1 from Type 2 diabetes is the most common application. A fasting C-peptide below 0.2 nmol/L in a patient with hyperglycemia strongly supports insulin deficiency, as seen in Type 1 diabetes. Values above 0.6 nmol/L in the same context favor preserved secretion.
- MODY (Maturity-Onset Diabetes of the Young) screening — Patients with a family history of non-autoimmune diabetes diagnosed before age 25 and who maintain C-peptide levels above 0.2 nmol/L three or more years after diagnosis are candidates for genetic testing per ADA guidelines.
- Hypoglycemia workup — When a patient presents with symptomatic hypoglycemia (plasma glucose ≤55 mg/dL during symptoms, consistent with Whipple's triad), simultaneous insulin and C-peptide measurements during the episode help distinguish endogenous hyperinsulinism (insulinoma) from exogenous insulin administration. An elevated insulin with suppressed C-peptide points to surreptitious insulin injection.
- Insulin resistance assessment — Elevated fasting insulin levels (above approximately 25 mIU/L, though reference ranges are assay-specific) in the context of normal or elevated glucose are used as supporting evidence of insulin resistance, relevant in evaluating polycystic ovary syndrome and metabolic syndrome.
- Post-bariatric or post-pancreatitis monitoring — Serial C-peptide measurements track residual beta-cell function following pancreatic surgery or inflammatory injury.
Decision boundaries
The following thresholds represent widely cited interpretive benchmarks, though clinical decisions integrate these values with history, autoantibody status, and imaging findings:
| Clinical question | Insulin value | C-peptide value | Interpretation |
|---|---|---|---|
| Beta-cell failure (Type 1) | Low or undetectable | < 0.2 nmol/L (fasting) | Consistent with near-total beta-cell loss |
| Preserved secretion (Type 2) | Variable | ≥ 0.6 nmol/L (fasting) | Supports endogenous insulin production |
| Endogenous hyperinsulinism | Elevated (≥ 3 mIU/L at glucose ≤55) | Elevated | Insulinoma or sulfonylurea effect |
| Exogenous insulin injection | Elevated | Suppressed | Factitious hypoglycemia |
The Endocrine Society and ADA both address insulin secretory thresholds in their respective clinical practice guidelines for diabetes management and hypoglycemia evaluation. The full endocrinology resource index provides additional context for understanding where these tests fit within broader hormone panel evaluation, including adrenal and pituitary assessments.
Patients found to have inadequate beta-cell reserve based on C-peptide results are typically evaluated for insulin therapy initiation or transition from oral agents, while those with evidence of insulin resistance may be assessed for GLP-1 and SGLT-2 inhibitor candidacy.
References
- American Diabetes Association (ADA) — Standards of Medical Care in Diabetes
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Centers for Medicare & Medicaid Services — Clinical Laboratory Improvement Amendments (CLIA)
- The Endocrine Society — Clinical Practice Guidelines
- NIDDK — Hypoglycemia (Low Blood Glucose)
The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)